Clinical trials: Prevention of Herpes Zoster
Prevention of Herpes Zoster
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
- Trial name
- NCT06961721
- Testing
- Herpes Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Prevention of : Herpes-Zoster
Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
Primary objective: Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month…
- Trial name
- NCT00561080
- Testing
- Zostavax
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC